Table 3.
Pretreatment-induced shifts in cocaine dose-effect function
| Pretreatment - genotype | A50 cocaine alone | A50 pretreatment | Fold shift | Rate decrease |
|---|---|---|---|---|
| Xanomeline - Wild-type | 1.58 [0.96 – 2.61] | 8.87 [4.05 – 19.4]* | 8.1 | −36% [−10 – −62] |
| Xanomeline - M1−/− | 1.81 [1.64 – 2.00] | 5.18 [3.50 – 7.65]* | 3.1 | −36% [−19 – −54] |
| Xanomeline - M4−/− | 0.99 [0.49 – 1.99] | 5.22 [1.86 – 20.3] | 8.6 | ns |
| VU0357017 - Wild-type | 1.25 [0.74 – 2.10] | 4.95 [2.81 –8.73]* | 5.5 | ns |
| VU0357017 - M1−/− | 1.43 [1.07 – 1.90] | 1.24 [0.67 – 2.28] | 1.0 | ns |
| VU0357017 - M4−/− | 2.04 [0.85 – 4.93] | 3.49 [1.84 – 6.62] | 2.1 | ns |
| 77-LH-28-1 - SW | 0.80 [0.51 – 1.27] | 2.32 [1.03 – 5.21] | 4.1 | −18% [−4 – −31] |
*
non-overlapping 95% confidence intervals. Fold shift in A50 was calculated in each mouse, then averaged. Rate decrease was calculated as the % decrease from cocaine alone in each mouse, then averaged across mice and cocaine doses.
ns: non-significant.